[{"from": "human", "value": "Describe this molecule. [C][N][Branch1][C][C][C][=Branch1][C][=O][C][=C][C][=C][N][=C][Branch1][#C][N][=C][Ring1][=Branch1][N][Ring1][=Branch2][C][C][C][C][C][Ring1][Branch1][N][C][=N][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][N][C][C][N][C][C][Ring1][=Branch1]"}, {"from": "gpt", "value": "The molecule is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably. Ribociclib was approved by the U.S. FDA in March, 2017 as Kisqali."}]